Whitehawk Therapeutics
WHWK
48 hedge funds and large institutions have $79.2M invested in Whitehawk Therapeutics in 2025 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 10 increasing their positions, 6 reducing their positions, and 5 closing their positions.
140% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 5
67% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 6
46% more capital invested
Capital invested by funds: $54.3M → $79.2M (+$24.9M)
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
17% more funds holding
Funds holding: 41 → 48 (+7)
8.8% more ownership
Funds ownership: 61.18% → 69.97% (+8.8%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SC
Stempoint Capital
New York
|
+$2.37M |
| 2 |
Two Sigma Investments
New York
|
+$711K |
| 3 |
EP
Eversept Partners
New York
|
+$597K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$567K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$253K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PLC
Peapod Lane Capital
Bedford Hills,
New York
|
-$577K |
| 2 |
Squarepoint
New York
|
-$159K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$94.7K |
| 4 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$67K |
| 5 |
Renaissance Technologies
New York
|
-$38.3K |
WHWK Hedge Fund Activity: Q4 2025 in Review
48 of the 8,228 institutional investors tracked by Wall St. Rank reported a position in Whitehawk Therapeutics (WHWK) for Q4 2025, worth a combined $79.2M — up 46% from $54.3M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new WHWK positions and 5 closed out — a net gain of 7 holders — while 10 added to existing stakes and 6 trimmed.
The largest buyer was Stempoint Capital, adding an estimated $2.37M. The largest seller was Peapod Lane Capital, exiting entirely with an estimated $577K sold.
- 48 institutional investors held Whitehawk Therapeutics (WHWK) as of Q4 2025, up from 41 in Q3 2025.
- Funds reported $79.2M of Whitehawk Therapeutics stock for Q4 2025, up 46% quarter-over-quarter.
- 12 funds opened new Whitehawk Therapeutics positions in Q4 2025 and 5 closed out, a net change of +7 holders.
- The largest Whitehawk Therapeutics buyer in Q4 2025 was Stempoint Capital, an estimated $2.37M added.
- The largest Whitehawk Therapeutics seller in Q4 2025 was Peapod Lane Capital, an estimated $577K sold.
Based on aggregated 13F filings for Q4 2025.